Gain Therapeutics
GANX
GANX
22 hedge funds and large institutions have $5.54M invested in Gain Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.48% less ownership
Funds ownership: 10.16% → 9.68% (-0.48%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Holders
22
Holding in Top 10
–
Calls
$289K
Puts
$11K
Top Buyers
| 1 | +$254K | |
| 2 | +$84.1K | |
| 3 | +$73.1K | |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$54.1K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$32.1K |
Top Sellers
| 1 | -$96.4K | |
| 2 | -$39.9K | |
| 3 | -$30.1K | |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$19.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$14.4K |